CASI Pharmaceuticals Inc banner
C

CASI Pharmaceuticals Inc
F:ENMN

Watchlist Manager
CASI Pharmaceuticals Inc
F:ENMN
Watchlist
Price: 2.28 EUR -1.72% Market Closed
Market Cap: €3.5m

Wall St Price Targets

ENMN Price Targets Summary
CASI Pharmaceuticals Inc

There are no price targets for ENMN.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
CASI Pharmaceuticals Inc Competitors:
Price Targets
ULTA
Ulta Beauty Inc
14% Upside

Revenue
Forecast

23% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
23% / Year
Past Growth
2% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 6 years is 2%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for CASI Pharmaceuticals Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for CASI Pharmaceuticals Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ENMN's stock price target?
Not Available

ENMN does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for CASI Pharmaceuticals Inc?
Projected CAGR
2%

Over the last 13 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 6 years is 2%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett